^
    Back
    Association details:
    Biomarker:ALK rearrangement
    Cancer:Non Small Cell Lung Cancer
    Drug Class:ALK inhibitor
    Direction:Sensitive
    Evidence:
    Evidence Level:
    Sensitive: A2 - Guideline
    New
    Source:
    ESMO.org
    Excerpt:
    Recommendation 12: first-line treatment of ALK-rearranged NSCLC....In ALK-rearranged NSCLC patients with localised distant progression and ongoing systemic control, continuation of treatment with ALK TKI in combination with local treatment of the progressing metastatic sites may be considered [A¼100% and III, B].
    Evidence Level:
    Sensitive: C3 – Early Trials
    Source:
    Target Oncol
    Title:

    Pathological Response and Tumor Immune Microenvironment Remodeling Upon Neoadjuvant ALK-TKI Treatment in ALK-Rearranged Non-Small Cell Lung Cancer

    Published date:
    06/23/2023
    Excerpt:
    Neoadjuvant ALKi therapy achieved an encouraging MPR rate of 75% and enhanced immune infiltration, suggesting its safety and feasibility for ALK+ resectable NSCLC.
    DOI:
    https://doi.org/10.1007/s11523-023-00981-7
    Evidence Level:
    Sensitive: C3 – Early Trials
    Source:
    ecancer
    Title:

    ALK-positive advanced non-small cell lung cancer patients with poor performance status: Outcomes in a real-world scenario

    Published date:
    06/07/2022
    Excerpt:
    The ALK-rearranged NSCLC patients with poor PS derived significant benefits with ALK inhibitors.
    DOI:
    https://doi.org/10.3332/ecancer.2022.1407